A listing of Type 2 Diabetes Mellitus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The AMPLIFY EP Registry is an observational, prospective, multi-center, non-randomized registry designed to obtain real world clinical experience with the TactiFlex Catheter Ablation system in the treatment of Atrial Fibrillation. Patient assessments will occur at pre- procedure and procedure, and 1 year post ablation.
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer.
To evaluate the efficacy and safety of 2 different doses of daplusiran/tomligisiran (50 mg every 4 weeks and 200 mg every 4 weeks for a total of 6 doses) followed by bepirovirsen 300 mg weekly for 24 weeks (with loading doses) in people living with chronic HBV on nucleos(t)ide analogue …
PURPOSE We aim to conduct a prospective observational study to test the central hypothesis that myocardial LM begins early after STEMI, as a response to myocardial hemorrhage and reperfusion injury, and determines future susceptibility to malignant arrhythmia. Study participants will be 175 (allowing for 25 dropouts) men and women 2 …
This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs).
Study is enrolling patients with IgAN (IgA Nephropathy) to find out if oral atrasentan will delay worsening of kidney functions in comparison to placebo. Subjects will be asked to complete questionnaires, do a physical exam, perform ECG, give blood and urine samples, and weigh themselves.
This is not a research study. We are not sharing any information for analyses. The device is FDA approved. IRB approval is required for device manufacturer to allow us to move forward with using therapy at Penn.